☆ 4.6 Article

Efficacy and safety profiles of dolutegravir plus lamivudine vs. bictegravir/emtricitabine/tenofovir alafenamide in therapy-naïve adults with HIV-1

CHINESE MEDICAL JOURNAL (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Infectious Diseases

Comparison of Virological Efficacy of DTG/ABC/3TG and B/F/TAF Regimens and Discontinuation Patterns in Persons Living with Advanced HIV in the Era of Rapid ART: A Retrospective Multicenter Cohort Study

Chun-Yuan Lee et al.

Summary: This study found that treatment regimens with DTG/ABC/3TC were more likely to be discontinued in advanced HIV patients compared to B/F/TAF, but there were no significant differences in viral suppression and virological failure between the two regimens. Therefore, individualized treatment approaches are crucial for advanced HIV patients.

INFECTIOUS DISEASES AND THERAPY (2023)

添加到收藏夹

Article Infectious Diseases

Treatment persistence of bictegravir/emtricitabine/tenofovir alafenamide and efavirenz plus lamivudine plus tenofovir disoproxil among HIV-1 patients newly starting treatment in Hunan Province in China

Jing Cao et al.

Summary: This study aims to assess the persistence with first-line BIC/FTC/TAF and EFV + 3TC + TDF in newly treated HIV-1 patients in Hunan Province, China. The study found that compared to EFV + 3TC + TDF, BIC/FTC/TAF patients were less likely to discontinue treatment, and the main reason for treatment discontinuation was economic issues.

BMC INFECTIOUS DISEASES (2023)

添加到收藏夹

Article Infectious Diseases

Immune response to ART initiation in advanced HIV infection

Karam Mounzer et al.

Summary: This study compared the immunological responses to commonly used antiretroviral therapy regimens among people with advanced HIV in the USA, and assessed virological outcomes and regimen persistence. The results showed that initiating ART with the B/F/TAF regimen was associated with faster CD4 cell count recovery and favorable virological outcomes compared with other regimens.

HIV MEDICINE (2023)

添加到收藏夹

Article Infectious Diseases

Effectiveness and tolerability of dolutegravir/lamivudine for the treatment of HIV-1 infection in clinical practice

Ines Suarez-Garcia et al.

Summary: The study assessed the effectiveness and tolerability of DTG/3TC in treatment-naive and virologically suppressed treatment-experienced individuals. The results showed that 91.4% and 93.8% of treatment-naive individuals achieved viral suppression at 24 and 48 weeks, respectively, after starting DTG/3TC. Among treatment-experienced individuals, 97.4% and 95.5% maintained viral suppression at 24 and 48 weeks, respectively, after switching to DTG/3TC.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2023)

添加到收藏夹

Article Infectious Diseases

An indirect comparison of 144-week efficacy, safety, and tolerability of dolutegravir plus lamivudine and second-generation integrase inhibitor-based, 3-drug, single-tablet regimens in therapy-naive people with HIV-1

Lee A. A. Evitt et al.

Summary: In treatment-naive people with HIV-1, the 2-drug regimen DTG + 3TC and 3-drug single-tablet regimens have been compared for their long-term efficacy and safety. The study found that DTG + 3TC offers comparable and durable efficacy with fewer serious adverse events compared to BIC/FTC/TAF and DTG/ABC/3TC after 144 weeks of treatment.

AIDS RESEARCH AND THERAPY (2023)

添加到收藏夹

Article Medicine, General & Internal

Bictegravir/emtricitabine/tenofovir alafenamide as initial treatment for HIV-1: five-year follow-up from two randomized trials

Paul E. Sax et al.

Summary: This study evaluated the long-term efficacy and safety of B/F/TAF in HIV-1 treatment. The results showed that B/F/TAF maintained high rates of virologic suppression over 5 years, with no treatment-emergent resistance and rare drug discontinuations due to adverse events.

ECLINICALMEDICINE (2023)

添加到收藏夹

Article Infectious Diseases

Dolutegravir plus lamivudine versus efavirenz plus tenofovir disoproxil fumarate and lamivudine in antiretroviral-naive adults with HIV-1 infection

Lisi Deng et al.

Summary: This study evaluated the efficacy and safety of dolutegravir plus lamivudine in ART-naive adults in China. The results showed that DTG + 3TC achieved virologic suppression more rapidly than EFV + TDF + 3TC after 12 and 24 weeks, and there were also significant changes in CD4 cell counts.

BMC INFECTIOUS DISEASES (2022)

添加到收藏夹

Article Immunology

Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide-Based 3-or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Results Through Week 144 From the Phase 3, Noninferiority TANGO Randomized Trial

Olayemi Osiyemi et al.

Summary: Switching to DTG/3TC showed durable efficacy and safety through 144 weeks with no virologic failure or resistance detected, supporting its use in virologically suppressed individuals with HIV-1.

CLINICAL INFECTIOUS DISEASES (2022)

添加到收藏夹

Article Immunology

Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy - naive adults with HIV-1 infection

Pedro Cahn et al.

Summary: The study assessed the efficacy and safety of dolutegravir lamivudine compared to dolutegravir with tenofovir disoproxil fumarate/emtricitabine in treatment-naive adults with HIV-1. The results showed that dolutegravir lamivudine was noninferior to dolutegravir with tenofovir disoproxil fumarate/emtricitabine in terms of virologic response. The dolutegravir lamivudine group had a lower rate of adverse events and less impact on renal and bone biomarkers. These findings support the use of dolutegravir lamivudine as a first-line treatment for HIV-1.

AIDS (2022)

添加到收藏夹

Article Pharmacology & Pharmacy

Effectiveness, Durability, and Safety of Dolutegravir and Lamivudine Versus Dolutegravir, Lamivudine, and Abacavir in a Real-Life Cohort of HIV-Infected Adults

Ines Mendoza et al.

Summary: The study did not demonstrate noninferiority in terms of virological effectiveness, but all effectiveness measures supported the use of Dolutegravir plus Lamivudine as an initial and switch option in a real-life cohort of treatment-naive and treatment-experienced patients. Additionally, the durability and safety of 2-DR were confirmed to be similar to that of 3-DR.

ANNALS OF PHARMACOTHERAPY (2022)

添加到收藏夹

Article Infectious Diseases

Metabolic Consequences of Antiretroviral Therapy

Caroline E. Diggins et al.

Summary: This review discusses the metabolic changes associated with antiretroviral therapy (ART) for the treatment of HIV, with a focus on newer ART agents. Research indicates that integrase inhibitor (INSTI)-based regimens and tenofovir alafenamide (TAF) are associated with weight gain, particularly in women and people of black race. Some studies suggest that this weight gain may have adverse effects on metabolic outcomes.

CURRENT HIV/AIDS REPORTS (2022)

添加到收藏夹

Article Immunology

Similar CD4/CD8 Ratio Recovery After Initiation of Dolutegravir Plus Lamivudine Versus Dolutegravir or Bictegravir-Based Three-Drug Regimens in Naive Adults With HIV

Javier Martinez-Sanz et al.

Summary: This study compared the impact of a 2-drug regimen with dolutegravir plus lamivudine to a 3-drug regimen based on other integrase strand transfer inhibitors (INSTIs) on the recovery of the CD4/CD8 ratio in people with HIV. The results showed no difference in the normalization rates of the CD4/CD8 ratio at 48 weeks between the two treatment strategies.

FRONTIERS IN IMMUNOLOGY (2022)

添加到收藏夹

Article Immunology

Effectiveness and Safety of Dolutegravir Versus Efavirenz-Based Antiviral Regimen in People Living With HIV-1 in Sichuan Province of China: A Real-World Study

Yang Tongtong et al.

Summary: This retrospective cohort study aimed to evaluate the effectiveness and safety of DTG and EFV antiretroviral regimens in China. The results showed that DTG-based regimens had better CD4 recovery and virologic suppression, with no significant difference in adverse events compared to EFV-based regimens. Therefore, DTG-based regimens may be considered as the preferred treatment option for initial HIV treatment.

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2022)

添加到收藏夹

Article Immunology

Dolutegravir Plus Lamivudine Dual-Drug Regimen in Treatment-Naive HIV-1-Infected Patients With High-Level Viral Load: Preliminary Data From the Real World

Fang Zhao et al.

Summary: This study indicates that the dolutegravir plus lamivudine two-drug regimen can be a successful treatment option for HIV-infected patients with HIV-RNA >= 500,000 copies/mL in China, with no significant differences observed after 48 weeks and no severe treatment-related adverse events.

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2022)

添加到收藏夹

Article Medicine, General & Internal

Determinants of long-term survival in late HIV presenters: The prospective PISCIS cohort study

Raquel Martin-Iguacel et al.

Summary: Late HIV diagnosis is associated with poorer outcomes. Two-year immune recovery after ART initiation is a good early predictor of long-term mortality. INSTI-based regimens are associated with higher rates of immune recovery and better survival.

ECLINICALMEDICINE (2022)

添加到收藏夹

Article Medicine, General & Internal

Real-world efficacy and safety of dolutegravir plus lamivudine versus tenofovir plus lamivudine and efavirenz in ART-naive HIV-1-infected adults

Jin Li et al.

Summary: This study evaluated the real-world efficacy and safety of DTG + 3TC in ART-naive HIV-1-infected adults in China. The results showed that DTG + 3TC achieved virological suppression more rapidly and stably, with better immunological response and less adverse drug effects.

MEDICINE (2022)

添加到收藏夹

Article Immunology

Predictors of Virological Failure and Time to Viral Suppression of First-Line Integrase Inhibitor-Based Antiretroviral Treatment

Ashima Pyngottu et al.

Summary: This study examined factors associated with treatment failure in HIV patients on InSTI-based regimens, finding that high baseline viral load and AIDS-defining events were linked to failure. CD4 cell counts between 200-500 and >500 cells/μL were protective. Risk factors for treatment failure were similar to those for older treatments.

CLINICAL INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Infectious Diseases

Antiretroviral treatment outcomes among late HIV presenters initiating treatment with integrase inhibitors or protease inhibitors

G. Schuettfort et al.

Summary: The study aimed to investigate the efficacy and safety of first-line antiretroviral therapy with integrase inhibitor or protease inhibitor-based regimens in patients with low CD4 cell counts and/or an AIDS-defining disease. Results showed no significant differences in discontinuation proportions or virological response at week 48 between late presenters starting first-line INI or PI-based ART regimens in a European cohort.

HIV MEDICINE (2021)

添加到收藏夹

Article Immunology

Late presentation for HIV impairs immunological but not virological response to antiretroviral treatment

Marta Rava et al.

Summary: Late presenters may not achieve complete immunological response despite the safety and effectiveness of initial ART in terms of viral suppression. The class and specific first-line ART regimen can impact the effectiveness and safety in late presenters.

AIDS (2021)

添加到收藏夹

Review Infectious Diseases

HIV-1 integrase strand transfer inhibitors: a review of current drugs, recent advances and drug resistance

Nokuzola Mbhele et al.

Summary: Antiretroviral therapy is crucial in controlling the HIV epidemic, with integrase strand transfer inhibitors (INSTIs) becoming more common. INSTIs have a higher genetic barrier to resistance, with DTG showing even higher resistance barriers and CAB being used as the first long-acting agent in HIV-1 treatment.

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2021)

添加到收藏夹

Review Infectious Diseases

HIV Treatment with the Two-Drug Regimen Dolutegravir Plus Lamivudine in Real-world Clinical Practice: A Systematic Literature Review

Rickesh Patel et al.

Summary: The two-drug regimen of dolutegravir plus lamivudine has shown durable efficacy for up to 3 years in phase III studies, demonstrating a high barrier to resistance in HIV patients. A systematic literature review of real-world evidence confirms high rates of virologic response and low rates of discontinuation in clinical practice, consistent with randomized controlled trial data.

INFECTIOUS DISEASES AND THERAPY (2021)

添加到收藏夹

Article Immunology

Brief Report: Virologic Response by Baseline Viral Load With Dolutegravir Plus Lamivudine vs Dolutegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled Analysis

Joseph Eron et al.

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2020)

添加到收藏夹

Review Pharmacology & Pharmacy

Comparative Clinical Pharmacokinetics and Pharmacodynamics of HIV-1 Integrase Strand Transfer Inhibitors: An Updated Review

Anthony T. Podany et al.

CLINICAL PHARMACOKINETICS (2020)

添加到收藏夹

Article Immunology

Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial

Jean-Michel Molina et al.

LANCET HIV (2018)

添加到收藏夹

Article Immunology

Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1:48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial

Eric S. Daar et al.

LANCET HIV (2018)

添加到收藏夹

Article Health Care Sciences & Services

Patient-Reported Symptoms Over 48Weeks Among Participants in Randomized, Double-Blind, Phase III Non-inferiority Trials of Adults with HIV on Co-formulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide versus Co-formulated Abacavir, Dolutegravir, and Lamivudine

David Wohl et al.

PATIENT-PATIENT CENTERED OUTCOMES RESEARCH (2018)

添加到收藏夹

Article Medicine, General & Internal

Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial

Paul E. Sax et al.

LANCET (2017)

添加到收藏夹

Article Medicine, General & Internal

Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial

Joel Gallant et al.

LANCET (2017)

添加到收藏夹

Article Microbiology

Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile

Manuel Tsiang et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.